How I manage patients with anticoagulation-associated bleeding or urgent surgery. by Sauter, Thomas C et al.
Review article: Biomedical intellegence | Published 14 March 2018 | doi:10.4414/smw.2018.14598
Cite this as: Swiss Med Wkly. 2018;148:w14598
How I manage patients with
anticoagulation-associated bleeding or urgent
surgery
Sauter Thomas C.a, Eberle Balthasarb, Wuillemin Walter A.c, Thiele Thomasd, Angelillo-Scherrer Annec, Exadaktylos
Aristomenis K.a, Erdoes Gaborb, Cuker Adamf, Nagler Michaele
a Department of Emergency Medicine, Inselspital, University Hospital Bern, Switzerland
b Department of Anaesthesiology and Pain Therapy, Inselspital, University Hospital Bern, Switzerland
c Division of Haematology and Central Haematology Laboratory, Luzerner Kantonsspital, Lucerne, Switzerland
d Institute for Immunology and Transfusion Medicine, Universitätsmedizin Greifswald, Germany
e Department of Haematology and Central Haematology Laboratory, Inselspital University Hospital, and Department for BioMedical Research, University of
Bern, Switzerland
f Departments of Medicine and Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
Summary
Antithrombotic treatment puts patients at risk of major
bleeding. Fast and adequate response to anticoagulant-
associated bleeding may not only stop the bleeding but
prevent severe complications. However, practical treat-
ment algorithms to guide physicians in emergency sit-
uations are lacking. Important principles that arise from
management of bleeding in general are (a) implementa-
tion of an in-house algorithm, (b) rapid identification and
treatment of the bleeding source, (c) adequate fluid re-
suscitation, (d) consideration of the application of tranex-
amic acid and (e) appropriate coagulation testing. We pre-
sent an algorithm for anticoagulant-associated bleeding
and urgent surgery, derived from available data and rec-
ommendations, and implemented at our institution. Deci-
sions regarding reversal agents or postponing surgery are
based on two questions: the occurrence of a life-threaten-
ing bleed or urgent indication for surgery, and the pres-
ence of a relevant drug level. Immediate application of
reversal agents is suggested if the clinical situation is ur-
gent and laboratory test results are delayed or unavail-
able. A relevant anticoagulant drug level is required in all
other cases. We discuss appropriate laboratory assays for
all commonly available anticoagulants, report respective
target ranges or expected values, discuss time intervals
before surgery, and present critical cut-off values to be
used as decision criteria. Specific and unspecific reversal
agents for all anticoagulants including the direct oral an-
ticoagulants will be presented. We aim to provide practi-
cal guidance for physicians in emergency situations. In ad-
dition, we summarise and discuss available experimental
and clinical data as well as recommendations provided by
scientific societies, authorities and manufacturers.
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Introduction
Any anticoagulation treatment is associated with an in-
creased risk of bleeding. Whereas the annual risk of any
bleeding is estimated to be 2-4%, the risk of major bleed-
ing increases in some patient populations to as much as
15%/year [1]. Intracranial haemorrhage is the most dan-
gerous adverse event; it is associated with a high risk of
death or permanent disability [2]. About 25% of intracra-
nial haemorrhages are linked to oral anticoagulant treat-
ment [3]. The anticoagulant-related bleeding risk is partic-
ularly relevant in the case of trauma. Uncontrolled bleed-
ing is the leading cause of death in trauma patients, but
it is regarded as potentially preventable [4, 5]. Physicians
treating patients with anticoagulation-associated bleeding
are confronted with a confusing number of drugs, labora-
tory tests and reversal agents. Often, clear treatment algo-
rithms are lacking and issues arise in terms of availability
of laboratory tests and reversal agents. Moreover, recom-
mendations issued by scientific societies, pharmaceutical
companies and regulatory authorities can be vague and
sometimes contradictory [6–8].
Management of anticoagulation-associated bleeding has
become more challenging as the number of available drugs
increases. Several direct oral anticoagulants targeting ei-
ther factor Xa (rivaroxaban, apixaban, edoxaban) or throm-
bin (dabigatran etexilate) have entered the market and are
increasingly being used [9]. Vitamin K antagonists, unfrac-
tionated heparin and low molecular heparin are still widely
utilised.
With this review, we aim to provide a practical approach
for emergency scenarios. We propose a pragmatic treat-
ment algorithm implemented in our institution (Inselspital,
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University Hospital, Bern, Switzerland). Our considera-
tions have largely been based on current statements issued
by scientific societies, regulatory authorities, companies
and experts, which we recognise is a limitation. This is
a reflection that high quality evidence in terms of ran-
domised controlled trials or prospective observational re-
search focused on clinical outcomes is scant [10]. Here
we collate important concepts of bleeding management
in general and regarding anticoagulant-associated bleeding
in particular, and discuss all aspects of available reversal
agents and laboratory aspects. We also summarise the man-
agement in case of urgent surgery. In addition, we provide
clear decision criteria in terms of drug levels and time in-
tervals focussing on all common anticoagulants (unfrac-
tionated heparin, low molecular weight heparins, vitamin
K antagonists, direct oral anticoagulants), but omitting
those drugs that are rarely used in Switzerland, such as fon-
daparinux.
General management of major bleeding
Implementation of algorithms
Several scientific guidelines provide recommendations for
the management of major bleeding, such as the current Eu-
ropean guideline on management of major bleeding and
coagulopathy following trauma, and the European Society
of Anaesthesiology guidelines for severe perioperative
bleeding [4, 11]. Implementation of in-house algorithms
and protocols is regarded as crucial for improving the care
of affected patients [12]. Detailed protocols improve com-
munication between multidisciplinary teams in a setting
where several diagnostic and therapeutic measures must
be taken simultaneously [13]. Indeed, implementation of
management protocols have been associated with im-
proved clinical outcomes [14–16].
Rapid identification and treatment of the bleeding
source
Identification and treatment of the bleeding source is the
critical first step in the management of patients with major
bleeding [4, 12]. Care teams must identify bleeding
sources as soon as possible by clinical examination and
early imaging (ultrasonography, contrast enhanced com-
puted tomography, angiography, or endoscopy). When the
bleeding source has been identified, patients should under-
go an immediate procedure to control the bleed, which of-
ten requires direct transfer to the operating theatre or the
angiography or endoscopy suite. This approach is support-
ed by the observation that 80% of trauma deaths occur
within the first hour after injury [12]. Indeed, distance from
a computed tomography (CT) scanner has been associat-
ed with mortality in observational studies [17]. Several ad-
ditional observational studies also support early bleeding
treatment [4, 18, 19].
Fluid resuscitation
In uncontrolled haemorrhage, fluids should be replaced in
accordance with the concept of “permissive hypotension”
[20, 21]. Although maintenance of an adequate blood pres-
sure is crucial to restore tissue perfusion in haemorrhag-
ic shock, which requires fluid replacement, excessive fluid
administration can result in relevant adverse events [22]. A
restrictive volume replacement strategy targeting a systolic
blood pressure of 80 to 90 mm Hg is therefore suggested,
at least in the absence of traumatic brain injury [20, 21].
This approach is supported by clinical data obtained in a
small randomised controlled trial [23], and several obser-
vational studies and meta-analyses [24–28]. Since colloid
use in volume resuscitation has been associated with coag-
ulopathy and kidney injury, a balanced isotonic crystalloid
solution is generally recommended [4]. Early administra-
tion of red blood cells and fresh frozen plasma (at least in a
ratio of 2:1) is another strategy employed to avoid crystal-
loid overinfusion and to mitigate dilutional coagulopathy,
with the goal of achieving a target haemoglobin range of
70 to 90 g/l [4]. Implementation of structured transfusion
protocols has been shown to improve survival, to prevent
organ failure and to reduce use of blood products and costs
[14]. In addition, prevention of hypothermia helps to avoid
coagulopathy, acidosis and hypotension associated with a
core body temperature less than 35°C.
Tranexamic acid
The anti-fibrinolytic agent tranexamic acid (Cyk-
lokapron®) is a valuable adjunct in the setting of acute
bleeding. It has few side effects, is inexpensive and is eas-
ily applied. In orthopaedic surgery, tranexamic acid re-
duced the need for blood transfusions by up to 40% [29].
In trauma patients, the efficacy of early administration
of 1 g tranexamic acid was tested in a large scale ran-
domised controlled trial including more than 20,000 pa-
tients (CRASH-2) [30]; the overall mortality was reduced
by 10%. A small case-control study suggests efficacy also
in the context of perioperative venous thromboembolism
prophylaxis with a direct oral anticoagulant [31]. Equally
important was that none of these studies reported an in-
crease of thromboembolic events, suggesting a good safety
profile. Only when tranexamic acid was given in higher
dose regimens in the context of cardiac surgery was a
small but significantly increased incidence of seizures ob-
served [32]. Based on the available evidence, published
reviews suggest that trauma-dose tranexamic acid should
also be administered to patients with anticoagulant-associ-
ated bleeding [33, 34].
Coagulation testing
Early and repeated determination of coagulation function
and platelet counts are recommended in all patients with
bleeding events [4]. Conventional coagulation tests are
not only useful to detect hereditary diseases (such as
haemophilia and von Willebrand’s disease) but also most
acquired disorders, namely fibrinogen deficiency, dissemi-
nated intravascular coagulation, vitamin K deficiency, liv-
er failure, acute traumatic coagulopathy, and anticoagulant
treatment [35]. The Inselspital screening panel for bleeding
emergencies contains prothrombin time (INR; Quick %),
activated partial thromboplastin time (aPTT), Clauss fib-
rinogen concentration, thrombin time, and the point-of-
care thromboelastometry assay (ROTEM®). ROTEM® or
thromboelastography (TEG®) are available in many insti-
tutions. These tests can rapidly detect fibrinogen deficien-
cy, thrombocytopenia and (severe) hyperfibrinolysis, and
are widely used to guide replacement therapy [11]. An an-
ti-Xa assay for screening of all Xa inhibitors, even though
data on its accuracy are lacking, could also be implemented
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as a screening test. Specific laboratory tests for the moni-
toring of anticoagulants are discussed further below.
Management of anticoagulant-associated
bleeding
General principles
Primary resuscitation of patients with suspected anticoag-
ulant-associated bleeding should follow the same gener-
al management strategies outlined above. However, major
haemorrhage is but one manifestation of anticoagulant-as-
sociated bleeding and is not always in conjunction with
trauma. A substantial proportion of patients on antico-
agulant treatment suffer a non-traumatic major haemor-
rhage, such as gastrointestinal bleeding or ruptured ab-
dominal aortic aneurysm; life-threatening bleeding events,
such as intracranial haemorrhage or (spontaneous or ia-
trogenic) spinal haematoma or pericardial tamponade, can
occur without hypovolaemia. Moreover, many patients on
anticoagulant treatment, though not bleeding actively, may
need to be prepared for major emergency surgery.
Thus, there are numerous important differences from non-
anticoagulant-associated bleeding, which must be ad-
dressed during management. First, specific and nonspe-
cific agents exist that can reverse the anticoagulant effect
within minutes and stop active bleeding rapidly [10] or re-
duce the risk of emergent surgery. Second, patients with
anticoagulant-associated bleeding remain at high risk of
thromboembolic complications due to their underlying dis-
ease (atrial fibrillation, venous thromboembolism, me-
chanical heart valve), because of the active bleeding event
and the associated administration of reversal agents [33].
The risks of bleeding and thrombosis must be monitored
and balanced carefully, and the period of reversal must be
kept as brief as possible. Third, knowledge of plasma lev-
els of the anticoagulant agent is important for management,
with specific laboratory assays required for individual anti-
coagulant drugs [34]. These issues will be discussed in de-
tail below.
Assessment of severity and urgency
Assessment of the severity of bleeding and urgency of in-
tervention is an important first step in patient management
to allocate subsequent treatment [4]. In patients with an
anticoagulant-associated bleeding event the question aris-
es whether and when a reversal agent should be applied.
Application of reversal agents may stop the bleeding rapid-
ly, but can also increase the risk of thromboembolic events
[33]. If the plasma level of the anticoagulant drug is not
known, reversal agents should not be used. Although a rel-
evant drug level can be estimated from the time of last
administration, this can be uncertain. Laboratory tests to
measure anticoagulant drug levels can take time, but they
have become increasingly available in the Swiss healthcare
setting. Thus, we use – and propose - an algorithm consid-
ering both the severity of bleeding as well as assay results
(fig. 1). Core aspects of this algorithm were utilised in the
pivotal study of idarucizumab, a reversal agent for dabiga-
tran etexilate [36]. This algorithm has been implemented
as an in-house guideline for Inselspital University Hospi-
tal, Bern, Switzerland.
Proposed treatment algorithm
In patients with supposed or known anticoagulant treat-
ment, assessment of urgency has a high priority (fig. 1).
The physician in charge must decide if the bleeding is life
threatening and requires immediate action. Identification
and treatment of bleeding sources is pivotal. Typical ex-
amples include severe haemorrhagic shock or extensive
intracranial haemorrhage. In these clinical situations, the
risk of bleeding-associated complications is higher than the
risk of thromboembolic complications related to reversal
agents. In the context of intracranial haemorrhage, sever-
al studies have demonstrated markedly improved clinical
outcomes if reversal agents are applied rapidly [6]. In our
practice, we treat patients suffering from life-threatening
bleeding with reversal agents without waiting for laborato-
ry results (fig. 1; left column) [6, 37]. We proceed similarly
in patients who require emergency surgery within 1 hour.
In contrast, in severely bleeding patients whose haemody-
namic and vital functions can be stabilised with treatment
according to protocol, we postpone the application of re-
versal agents until the specific anticoagulant drug level has
been determined with the appropriate laboratory test (dis-
cussed below) (fig. 1; central “severe bleeding” scenario).
For severe bleeding events we use a time cut-off of 1 hour,
because all anticoagulant drug levels can be determined
and communicated within this timeframe at our institution,
but this can be tailored to accommodate laboratory timings
at other institutions. Any further patient intake of antico-
agulant drugs is of course stopped in both these scenar-
ios. The management of mildly bleeding, haemodynami-
cally stable patients is shown in the right column of figure
1. Patients in this category may require surgery that can be
scheduled 24 hours or more in the future. Generally, such
patients will not receive reversal agents and anticoagulant
intake will be stopped. Treatment decisions, however, for
patients with a high thromboembolic risk are assessed on a
case-by-case basis (see below).
It is important to note that a panel of screening laboratory
tests (blood count, PT, aPTT, fibrinogen and thrombin
time) as well as drug-specific assays (discussed below) are
required before and after treatment to detect haemostatic
disorders and to document treatment efficacy. The drug-
level cut-offs for use of reversal agents are shown in figure
1 (left table) and are discussed below.
Anticoagulant drug levels and activity may be estimated by
considering the time of last administration. This is, howev-
er, fraught with uncertainty as a result of incomplete med-
ication records, the patient’s memory or mental health sta-
tus and many other pitfalls.
Assessing the thrombotic risk
Patients with anticoagulant-associated bleeding or requir-
ing urgent surgery are at increased risk of thromboembolic
complications. This can arise as a result of the underlying
disease, the acute event and, potentially, the application
of reversal agents. Knowledge of the underlying throm-
boembolic risk is important for management [38]. Scien-
tific societies have summarised epidemiological data and
created risk categories with regard to peri-interventional
procedures as reported by the American College of Chest
Physicians (ACCP), but these data can also be considered
in the case of bleeding as well [38]. Table 1 summarises
the data and groups patients into three risk categories. In
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patients with an intermediate or high thromboembolic risk,
anticoagulant treatment should ideally be resumed within
24 hours, because the thromboembolic risk will increase
further owing to procedural risks and the effect of reversal.
Anticoagulants and their reversal agents
Unfractionated heparin
Because of its short half-life, unfractionated heparin is still
ubiquitously used in the perioperative setting and in the in-
tensive care unit. Administered intravenously, its biologi-
cal half-life varies according to the dosage and is typically
between 30 minutes and 2.5 hours [8]. The antithrombot-
ic effect is usually gone 4 hours after discontinuation and
surgery can be performed safely. Therefore, use of a re-
versal agent can be avoided in most cases. When rever-
sal is required, protamine (as hydrochloride or sulphate) is
employed. It is a small, basic cationic protein made from
salmon sperm that binds to the anionic glycosaminoglycan
heparin, acting as a stoichiometric reversal agent that can
rapidly inactivate unfractionated heparin. One unit (0.01
mg) of protamine will neutralise approximately 1 unit of
heparin. Protamine has been used worldwide every day in
cardiac surgery for decades, but has well-recognised ad-
verse events such as hypotension, pulmonary vasoconstric-
Figure 1: Management of patients with anticoagulant-associated bleeding or urgent surgery. Proposal for a treatment algorithm detailing labo-
ratory tests, cut-off values and administration of reversal agents.INR = international normalised ratio; aPTT = activated partial thromboplastin
time; UFH = unfractionated heparin; LMWH = low molecular weight heparin; VKA = vitamin K antagonists
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tion, anaphylactoid reactions and thromboembolic com-
plications [6, 8, 40]. In accordance with guidelines, we
recommend the slow application of 1 unit of protamine (di-
luted in normal saline) per unit unfractionated heparin ad-
ministered within the previous 3 hours if the heparin was
stopped within <1 hour previously or in the case of anti-
Xa activity > 0.35 U/ml (with a maximum dose of 5000
units). We propose the application of 0.5 units of protamine
per unit unfractionated heparin, if the heparin was stopped
within the previous 3 hours or anti-Xa activity is >0.1 U/
ml [6, 8]. Protamine should not be given if the ant-Xa level
is ≤0.1 U/ml. Protamine dosage can also be monitored us-
ing the point-of-care activated clotting time (ACT) test.
Low molecular weight heparin
Low molecular weight heparin consists of short chains of
polysaccharides, which have a longer half-life (3–5 hours)
than unfractionated heparin, and this permits a once or
twice daily subcutaneous application for treatment and
prophylaxis of thromboembolism [8]. However, owing to
the molecular structure, only about 50% of the anticoag-
ulant effect of low molecular weight heparin can be re-
versed by protamine, with no other reversal agent currently
available. To counteract low molecular weight heparin an-
ticoagulation with protamine, we suggest giving an intra-
venous dose of 5000 units of protamine slowly (preferably
diluted) if a therapeutic dose of low molecular weight he-
parin was given within the last 8 hours, or if the anti-Xa
activity is >0.5 U/ml (fig. 1, right table). A dose of 2500
units is given if a therapeutic dose of low molecular weight
heparin were administered more than 8 but ≤12 hours pre-
viously or if anti-Xa activity is between 0.3 and 0.5 U/ml.
We suggest withholding protamine in all other cases.
Vitamin K antagonists
Vitamin K antagonists block vitamin K epoxide reductase,
among other effects, thus inhibiting synthesis of clotting
factors II, VII, IX and X [7, 41]. This effect lasts for sev-
eral days and administration of exogenous agents are re-
quired to stop effects of vitamin K antagonists in patients
with active bleeding or prior to urgent surgery. Three
agents are available to reverse vitamin K antagonist anti-
coagulant effects.
1. Vitamin K itself which provides the substrate for syn-
thesis of the aforementioned clotting factors. Even
though repeated doses of vitamin K should be given
(in emergencies by slow intravenous injection injec-
tion; fig. 1, right table) [6], the earliest physiological
effect is 3 hours after administration, rendering this an
inadequate treatment for immediate vitamin K antago-
nist reversal.
2. Fresh frozen plasma, which contains all coagulation
factors at approximately physiological levels, has been
used for vitamin K antagonist reversal for decades as
it is inexpensive and widely available. However, treat-
ment with fresh frozen plasma is associated with dis-
advantages [6], such as a considerable time delay un-
til a correction of anticoagulant effects is observed, a
large fluid load, which increases the risk of transfu-
sion-associated circulatory overload, and also, albeit a
very small, residual risk of transfusion-related acute
lung injury. Thus, recent guidelines recommend vit-
amin K antagonist reversal with fresh frozen plasma
only if the more specific reversal option, prothrombin
complex concentrate (see below) is not available [6].
3. “Four-factor” prothrombin complex concentrate,
which contains vitamin K-dependent coagulation fac-
tors (factors II, VII, IX, X; proteins S, C, Z) in variable
amounts. Prothrombin complex concentrate is regard-
ed as the vitamin K antagonist reversal agent of choice
because of its rapid action, small volume load and low
risk of transfusion reactions [6, 7, 42]. Its efficacy has
been demonstrated in two randomised controlled trials
focusing on patients with major bleeding [43] and ur-
gent surgery [44]. In the setting of intracranial haem-
orrhage, several observational studies suggest superi-
ority of prothrombin complex concentrate over fresh
frozen plasma with regard to time until reversal,
haematoma expansion, mortality and functional out-
comes [6]. However, prothrombin complex concen-
trate may increase the risk of thromboembolic compli-
cations and not more than 2400 units should be given
initially [45] (fig. 1, right table).
Dabigatran etexilate (Pradaxa®)
The main advantage of direct oral anticoagulants is their
relatively short half-life, which in the case of dabigatran is
12 to 14 hours [46]. Thus, stopping the drug is sufficient in
many cases of bleeding and urgent surgery. Nevertheless,
development of a reversal agent was considered an impor-
tant objective to improve patient care. Idarucizumab, a hu-
manised monoclonal antibody fragment which binds to and
inactivates dabigatran, has been developed and tested in a
single-arm interventional study (n = 503) [36, 47]. Consec-
utive infusion of two vials, each containing 2.5 g of idaru-
cizumab, reverses the anticoagulant effect of dabigatran
rapidly and completely, both in laboratory testing and clin-
ically. Thus, idarucizumab (Praxbind®) has been licenced
in the US (Food and Drug Administration, FDA), in Eu-
Table 1: Patient-related risk for thromboembolism according to anticoagulation indication; adapted from [38, 39].
Indication Low risk* Intermediate risk† High risk‡
Mechanical heart valve Bileaflet mechanical aortic valve without
risk factors for stroke
Bileaflet mechanical aortic valve with risk fac-
tors for stroke
Any mechanical mitral valve
Any caged-ball or tilting-disc valve
Recent stroke/TIA (< 6 months)
Atrial fibrillation CHA2DS2-VASc score 0 to 3 CHA2DS2-VASc score 4 to 7 CHA2DS2-VASc score 8 to 9
Recent stroke/TIA (<3 months)
Rheumatic valvular disease
Venous thromboembolism VTE >1 year VTE within <1 year
Recurrent VTE
Active cancer
Recent VTE (<3 month)
Severe thrombophilia¶
TIA = transient ischaemic attack; VTE = venous thromboembolism * risk of arterial thromboembolism < 4% per year; VTE < 2% per month † risk of arterial thromboembolism
4-10% per year; VTE 4-10% per month ‡ risk of arterial thromboembolism > 10% per year; VTE > 10% per month ¶ Deficiency of protein C, protein S, or antithrombin; antiphos-
pholipid antibody syndrome
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rope (European Medical Agency, EMA) and Switzerland
(Swiss Agency for Therapeutic Products, Swissmedic). In
our practice so far, application of idarucizumab has been
simple, effective and safe, even in special situations [48].
We suggest administration of idarucizumab as the sole
reversal agent in dabigatran-treated patients with severe
bleeding or need for urgent surgery (fig. 1). Dialysis might
be considered in patients with renal failure if idarucizumab
is not available, but this only removes approximately two
thirds of dabigatran and typically requires several hours
[49].
Oral factor Xa inhibitors: rivaroxaban (Xarelto®),
apixaban (Eliquis®) and edoxaban (Lixiana®)
The oral factor Xa inhibitors rivaroxaban, apixaban and
edoxaban share important characteristics with dabigatran,
in particular the short half-life (5–15 hours) [46]. Thus,
stopping these drugs is adequate in many patients. Four-
factor prothrombin complex concentrate has been suggest-
ed for nonspecific reversal of oral factor Xa inhibitors [10].
The effects have been variable in a number of animal and
ex-vivo studies [50–53]. Prothrombin complex concentrate
corrected the prothrombin time in healthy volunteers tak-
ing rivaroxaban, suggesting potential efficacy [54, 55]. In
addition, a number of case reports exist [56–58]. Consis-
tent with existing guidelines [6, 59], we apply prothrom-
bin complex concentrate at a dosage of 50 U per kg body
weight in patients with (a) life-threatening bleeding, (b) se-
vere bleeding and relevant drug levels, or (c) need for ur-
gent surgery and relevant drug levels (fig. 1). We general-
ly do not use recombinant factor VIIa because of potential
adverse events and a paucity of data.
Future perspectives
Two agents are currently under development for the rever-
sal of factor Xa inhibitors. Andexanet alfa is a recombinant
protein mimicking factor Xa but lacks any coagulant ac-
tivity [60]. Andexanet alfa was effective and well tolerated
in animal studies and healthy volunteers [60, 61]. Effica-
cy and safety have been tested in an open-label single-arm
interventional study in elderly patients with acute major
bleeding (interim report n = 67) [62]. A partial reversal of
rivaroxaban, apixaban or enoxaparin was observed with re-
gard to anti-Xa activity. Clinical efficacy was rated to be
good in the majority of patients. However, a high rate of
thromboembolic events, as well as deaths, have been ob-
served; this has been suggested to have resulted from the
baseline thrombotic risk of the study patients (but it might
indeed reflect a certain prothrombotic risk). Andexanet al-
fa was only moderately effective in reversing low molecu-
lar weight heparin in animal experiments [42, 63].
Ciraparantag is another agent developed to reverse the ef-
fect of factor Xa inhibitors [64]. It is a positively charged
molecule that binds directly to these molecules. It has been
tested in a phase I/II study in healthy volunteers [65]. An-
other study is ongoing in healthy volunteers taking rivarox-
aban (NCT03172910). Clinical data obtained in patients
are still lacking.
Measurement of anticoagulants
Monitoring of drugs requires established target ranges. The
definition of a target range is based on comprehensive data
on efficacy and safety outcomes at defined anticoagulant
concentrations or activity levels. These criteria are met for
vitamin K antagonists only. It is, however, common prac-
tice to monitor treatment with unfractionated heparin as
well [8]. One of the main benefits of direct oral anticoag-
ulants is that routine laboratory monitoring of anticoagu-
lant activity is not necessary. All direct oral anticoagulants
have been studied at fixed doses and no target ranges of
drug levels are established. Knowledge of the anticoagu-
lant drug level is, however, important in certain clinical sit-
uations [34] and the bleeding patient on anticoagulants is a
good example where administration of reversal agents may
be lifesaving. Drug concentrations were measured in some
of the clinical studies, and an “expected range” for peak
and trough levels have been published. For interpretation
of test results, it is important to know whether they were
measured at peak level (corresponding to the time point
tmax after ingestion; table 2) or at the trough level (before
the next application). Knowledge of the appropriate labo-
ratory test and expected values is necessary to put results
into context. In addition, treating physicians must be aware
that large interindividual variabilities exist [66]. Table 3 il-
lustrates appropriate laboratory tests for commonly avail-
able anticoagulants and reports target ranges or expected
values.
Vitamin K antagonists
Prothrombin time (in Switzerland usually expressed in re-
lation to standardised human plasma as a prothrombin ratio
[PR] or Quick %) has been used for monitoring of vitamin
K antagonists ever since the discovery of “sweet clover
Table 2: Characteristics of commonly used anticoagulants: mechanism of action, pharmacokinetics and elimination.
Agent Mechanism of action tmax Half-life Elimination Prolonged half-life
Rivaroxaban
(Xarelto®)
2–4 h 5–9 h 66% renal, 28% faecal Older patients, renal impairment
Apixaban
(Eliquis®)
3–4 h 8–15 h 30% renal, 70% faecal Older patients, renal impairment
Edoxaban
(Lixiana®)
Inhibits factor Xa
1–2 h 9–10 h 50% renal Older patients, renal impairment
Dabigatran
(Pradaxa®)
Inhibits thrombin 0.5–2 h 12–14 h Renal Older patients, renal impairment
VKA
(Marcoumar®, Sin-
trom®)
Inhibits vitamin K metabo-
lism and reduces Factor
II*
48–72 h+ ca. 160 h+ Hepatic metabolism, renal elimination Multiple interactions with medications
as well as nutritional interactions, im-
paired hepatic function
UFH Activates antithrombin 30–120 min 30–150 min Liver Hepatic impairment, high doses
LMWH Inhibits factor Xa 2–4 h 3–5 h Mostly renal Renal impairment
LMWH = low molecular weight heparin; UFH = unfractionated heparin; VKA = vitamin K antagonist * And other coagulation factors
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disease” [69]. Standardisation of thromboplastins using the
international sensitivity index (ISI; based on a WHO stan-
dard) has enabled the implementation of the international
normalised ratio (INR). Using the INR, the intensity of an-
ticoagulation in individual patients is comparable between
individual laboratories using different reagents worldwide.
Results of large epidemiological studies have led to a pre-
cise definition of the optimal target range, which is 2.0 to
3.0 for most patients and indications [70]. INR values <1.3
or PR >70% Quick are regarded as sufficient for most sur-
gical procedures and in the case of major bleeding.
Unfractionated heparin
It is common practice to monitor treatment with unfrac-
tionated heparin though there are major methodological
concerns and very few clinical studies support this ap-
proach [8, 71]. The aPTT is recommended most often,
but it is associated with important shortcomings: a large
variability among different reagents and a high sensitivity
to other factors that are prevalent in critically ill patients
[72–74]. In contrast, chromogenic anti-Xa assays have
been developed to determine heparin concentration accu-
rately (though inconsistencies among reagents exist) [75].
Indeed, monitoring with anti-Xa assays was associated
with fewer complications than monitoring with aPTT in
a small randomised controlled trial [76]. The aPTT target
range must be determined by every laboratory in relation to
either anti-Xa levels or a protamine/heparin titration curve
[8]. In our institution, the aPTT target range is 46–70 sec;
the cut-off for surgery and major bleedings is the upper
limit of the reference range (35 sec; fig. 1). In terms of an-
ti-Xa activity, the target range is 0.35–0.7 U/ml and a rel-
evant cut-off is 0.1 U/ml (fig. 1) [8]. The thrombin time is
also a very sensitive laboratory test to monitor effects of
unfractionated heparin, although its response curve is not
linear. However, a normal thrombin time essentially ex-
cludes the presence of unfractionated heparin.
Low molecular weight heparin
The dosage of low molecular weight heparin is based on
body weight, and laboratory monitoring is usually not re-
quired [8]. However, knowledge of the plasma concentra-
tion is important in the case of major bleeding or urgent
surgery. Drug-level adapted treatment is recommended in
special situations such as pregnancy, extreme body weight
or renal failure [77]. Anti-Xa activity is the most accurate
test and is recommended for the measurement of low mol-
ecular weight heparin [8]. Target ranges are 0.6–1.0 U/ml
(twice daily dosing) and 0.9–1.6 U/ml (once daily dosing)
(fig. 1, left table). An appropriate cut-off for most opera-
tions is 0.15 U/ml.
Dabigatran etexilate
Thrombin time is a widely available assay and is extremely
sensitive to the thrombin inhibitor, dabigatran. Even mod-
erate dabigatran drug levels prolong thrombin time beyond
its range of measurement [67]. Thus, a normal thrombin
time rules out the presence of dabigatran. Adapted assays
have been developed to measure dabigatran drug concen-
tration across the normal therapeutic range [68]. This “di-
luted thrombin time” provides adequate accuracy, both as
an in-house assay and as commercially available test kit
(HEMOCLOT®, HYPHEN BioMed, Neuvillesur-Oise,
France) [78]. The ecarin clotting time is another assay de-
veloped to measure dabigatran activity, but important re-
producibility issues remain [68]. Expected dabigatran con-
centrations at peak and trough are reported in table 3.
Cut-off values, which are relevant for considering reversal
agents or postponement of surgery, are 50 ng/ml in the case
of major bleeding or surgery associated with a low bleed-
ing risk, and 30 ng/ml in the case of life-threatening bleed-
Table 3: Laboratory tests, expected drug levels, critical drug levels and required time interval before intervention.
Drug Laboratory assay Expected drug levels*
(dosage)
Proposed cut-off for surgery Time interval before operations, inter-
ventions and spinal anaesthesia
Rivaroxaban
(Xarelto®)
Anti-Xa activity
(PT/INR)
Peak: 270 ng/m (189–419)†
Trough: 26 ng/ml (6–87)†
(20 mg daily)
<50 ng/ml for urgent surgery and low
bleeding risk
<30 ng/ml for high-risk surgery
≥24 h if bleeding risk of surgery is low/ in-
termediate
≥48 h in case of high bleeding risk with
surgery, elderly patients, renal failure¶
Apixaban
(Eliquis®)
Anti-Xa activity
(PT/INR)
Peak: 171 ng/ml (91–321)†
Trough: 103 ng/ml (41–230)†
(5 mg twice daily)
<50 ng/ml for urgent surgery and low
bleeding risk
<30 ng/ml for high-risk surgery
≥24 h if bleeding risk of surgery is low/in-
termediate
≥48 h in case of high bleeding risk with
surgery, elderly patients, renal failure¶
Edoxaban
(Lixiana®)
Anti-Xa activity
(PT/INR)
Peak: 170 ng/ml (120–250)‡
Trough: 22 ng/m (10–40)‡
(60 mg daily)
<50 ng/ml for urgent surgery and low
bleeding risk
<30 ng/ml for high-risk surgery
≥24 h if bleeding risk of surgery is low/in-
termediate
≥48 h in case of high bleeding risk with
surgery, elderly patients, renal failure¶
Dabigatran
(Pradaxa®)
Diluted thrombin time
Ecarin clotting time
(thrombin time)
Peak: 184 ng/ml (64–443)†
Trough: 90 ng/ml (31–225)†
(150 mg twice daily)
<50 ng/ml for urgent surgery and low
bleeding risk
<30 ng/ml for high-risk surgery
≥36 h if bleeding risk of surgery is low
≥48 h in the event of high bleeding risk
with surgery, elderly patients, renal fail-
ure¶
VKA
(Marcoumar®, Sin-
trom®)
INR 2.0–3.0 (target range) INR <1.3 >5 to 7 days
UFH aPTT
Anti-Xa activity
0.35–0.7 U/ml (target range) aPTT <35 s or
anti-Xa ≤0.1 U/ml
≥4–6 h (longer in case of renal failure, el-
derly patients, subcutaneous application)
LMWH Anti-Xa activity 0.6–1.0 U/ml (target range twice daily)
0.9–1.6 U/m (target range once daily)
Anti-Xa ≤0.15 U/ml ≥12 h (50–100 U/kg body weight)
≥24 h (150–200 U/kg body weight)
≥48 h in the case of high bleeding risk
with surgery, elderly patients, renal fail-
ure¶
aPPT = activated partial thromboplastin time; INR = international normalised ratio; LMWH = low molecular weight heparin; PT = prothrombin time; UFH = unfractionated heparin
* adapted from [67, 68] † median; 5th to 95th percentile ‡ median; interquartile range ¶ in patients with renal failure, the interruption interval shall be extended by 1 to 2 days
(depending on the severity and the bleeding risk of the intervention) or drug level determined using an appropriate laboratory test
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ing or surgery associated with a high bleeding risk (table 3;
fig. 1) [37].
Oral factor Xa inhibitors: rivaroxaban, apixaban, and
edoxaban
Factor Xa inhibitors affect the PT and PT-based assays, and
therefore these assays have been proposed to estimate drug
levels [67]. However, most authors do not suggest use of
PT-based assays because of limited sensitivity and speci-
ficity, and large variation among different reagents [68].
However, the point-of-care coagulometer CoaguChek® XS
detects peak rivaroxaban levels with high sensitivity [79].
Anti-Xa assays have been developed for the measurement
of oral factor Xa inhibitors [80, 81]. A high accuracy and
consistency has been demonstrated, particularly for ri-
varoxaban plasma concentrations [66]. Expected drug lev-
els at peak (3 hours after intake) and trough (24 hours after
intake) with a 20 mg dose are shown in table 3. Scientific
societies recommend considering reversal agents or post-
ponement of surgery at an anti-Xa level of 50 ng/ml in the
case of major bleeding or urgent surgery, and at 30 ng/ml
in the case of life-threatening bleeding or surgery with a
high risk of bleeding [37].
Management of anticoagulants in the case of
urgent surgery or interventions
The periprocedural risk of patients treated with antithrom-
botic drugs is determined by four main issues, which must
be considered: (1) the thromboembolic risk of the under-
lying disease which corresponds to the indication for anti-
coagulation (patient-related risk), (2) the thromboembolic
risk associated with the planned surgery or the clinical sit-
uation (surgical risk factors), (3) the bleeding risk due to
the anticoagulant drugs and the drug level at the time of
surgery, and (4) the bleeding risk of the surgery and the po-
tential consequences of a bleeding complication. All issues
are discussed in detail elsewhere [38, 39, 82, 83].
Patient-related thromboembolic risk is discussed above
and summarised in table 1 [38, 39]. Patients with a high
risk should not be left without anticoagulation therapy for
a long period of time [38, 39]. The same holds true for pa-
tients undergoing a surgical procedure with a high throm-
boembolic risk (cancer surgery, cardiovascular surgery, ex-
tensive abdominal, thoracic or pelvic surgeries, hip frac-
ture, or major trauma) [38, 39]. Nevertheless, a prophy-
lactic dose of anticoagulation treatment should be started
about 6 hours postoperatively and a therapeutic dose
should be started about 24 hours postoperatively.
The third important aspect is the bleeding risk of the in-
tended surgery or intervention. No interruption of antico-
agulation treatment is necessary in procedures with mini-
mal bleeding risk, such as cataract surgery and most der-
matology or dental procedures; for colonoscopy, gastroin-
testinal endoscopy, or arthroscopy decisions should be
made on a case by case basis [39]. In contrast, anticoagula-
tion must be interrupted adequately prior to surgeries with
a high bleeding risk (intracranial or intraspinal surgery,
other major surgery in general).
In the event of emergency surgery and a high bleeding
risk (potentially also in cases with an intermediate bleeding
risk), use of reversal agents is necessary in virtually all pa-
tients treated with a vitamin K antagonist. Specific drugs
have been discussed above. Reversal agents are rarely nec-
essary in the case of single anticoagulation treatment with
unfractionated heparin. Surgery can usually be conducted
4 hours after stopping unfractionated heparin. Determina-
tion of anti-Xa activity can help to adapt the time interval
(in the case of high urgency or renal impairment; see table
3). When low molecular weight heparin has been used and
paused, most operations can be done after 12 hours (pro-
phylactic dose) or 24 hours (therapeutic dose; table 3).
Again, determination of anti-Xa levels can help to adapt
the time interval. Protamine can be considered in special
situations (table 3) and andexanet or ciraparantag might be
options in the future. Manufacturers of direct oral antico-
agulants recommend relatively long intervals between ad-
ministration of the last dose and interventions, up to 72
hours in the case of dabigatran. However, clinical data
from large registries suggest that short-term interruption is
a safe approach [82]. Considering these data together with
manufacturers’ recommendations, we suggest the time in-
tervals mentioned in table 3. Again, determination of the
drug level can help to adapt the waiting period in order to
reduce or prolong the time to intervention (table 3).
Conclusions
Management of patients with anticoagulant-associated
bleeding or urgent surgery is challenging. We present a
simple treatment algorithm that is based on the assessment
of severity and urgency as well as the measurement of drug
levels. In addition, we provide information regarding ap-
propriate drug levels and time intervals to follow in emer-
gency situations. If implemented as a treatment protocol,
this algorithm might help emergency and perioperative
teams to provide high quality care and to minimise inher-
ent risks of bleeding and thrombosis.
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